Launched from a research program begun in 2016 at SENS Research Foundation, since founding in 2019 we have raised ~$18M in three private equity rounds, along with generous grants from NIH, NAM, and Longecity.
Atherosclerosis causes 4 of 10 deaths, with drug treatment limited to incremental advances in lipoprotein management.
The primary risk factor and cause of atherosclerosis is aging, thus we are targeting the root causes of the disease with our first drug product.
Our mission: reverse the disease, radically reduce its trillion-dollar burden, and save countless lives .
- Targeting oxidized cholesterol, a known driver of atherosclerosis with no current treatment options
- Addressing the root cause of atherosclerotic inflammation, rather than downstream signaling
- 7KC is a target with no biological function, which can be removed systemically without any negative effects
- Efficient clinical development without the time and intricacies of a complex biologic approach
- Enormous cross-disease and healthspan potential; primary CAD lead with pipeline development for neurodegenerative diseases, liver failure, and heart failure
7KC defunctionalizes plaque-clearing macrophages into diseased foam cells disease progresses, foam cells accumulate, and plaque grows. Removing 7KC rehabilitates foam cells and the natural plaque-clearing response.
We are clinic ready!
We are one of the first UK Innovation Passport recipients
We've completed successful FDA pre-IND and UK SAM
cGMP manufacturing in the fill/finish stage
We are in contract for phase 1, preclinical completes in Q1 2025
efficient clinical path with early efficacy data
safety data complete in 2024
phase 2, with plaque reduction endpoint, in 2026
Co-founders
Mike Kope, CEO of Corp. Affairs, 30+ years in biopharma with product launches and corporate exits
Matthew O’Connor, CEO of Sci. Affairs, 20+ years as a leader in the field of rejuvenation biotech
Amelia Anderson, Head of Computational Chemistry
World class clinical advisors
Prof. Prediman K. Shah, Founder and Director of the Oppenheimer Atherosclerosis Center, Cedars-Sinai Hospital
Prof. Michael Farkouh, Associate Dean for Research and Clinical Trials, Cedars-Sinai Hospital
Prof. Stephen Nicholls, Director of the Victorian Heart Institute, Monash University
… and, launching in 2025, the state-of-the-art in AI-based generative cyclodextrin development
